|
|
|
| Effect of Lichong Decoction on the expression of immune escape factors in the mice with heterograft uterine fibroids |
| LIU Yu LI Donghua WANG Wenna WEI Chao QIU Tiantian |
| College of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China |
|
|
|
Abstract Objective To explore the effects of Lichong Decoction on the expression of indoleamine 2,3-dioxygenase (IDO) and forkhead winged helix transcription factor-3 (Foxp3) in xenograft mice with human uterine fibroids from the perspective of immune escape mechanism. Methods Thirty-two female mice of CB-17 scid were divided into normal group, model group, Lichong Decoction group and positive drug group according to completely randomized method, with 8 mice in each group. The animal model of uterine leiomyoma was established by xenotransplantation. After successful modeling, Lichong Decoction group was given Lichong Decoction, positive drug group was given Mifepristone, normal group and model group were given the same amount of saline, and tissue samples were collected after 4 weeks of continuous intervention. The histopathological changes of the uterine smooth muscle of mice in each group were observed by HE staining, and the expression of IDO in the smooth muscle tissue of mice in each group was detected by Western blot, and the expression of Foxp3 mRNA was detected by Real-time PCR. Results Compared with model group，the thickness of endometrium and muscle layer of mice in Lichong Decoction group was reduced, and the content of fibrous tissue was less compared with the model group. The expression of IDO and Foxp3 mRNA in uterine smooth muscle tissue of mice was significantly reduced in Lichong Decoction group (P ＜ 0.05 or P < 0.01). Conclusion Lichong Decoction has the effect of inhibiting the occurrence and development of uterine fibroids, and its pharmacological mechanism may be related to blocking tumor immune escape.
|
|
|
|
|
|
[1] Faustino F，Martinho M，Reis J，et al. Update on medical treatment of uterine fibroids [J]. Eur J Obstet Gynecol Reprod Biol，2017，216（6）：61-68.
[2] Al-Hendy A，Myers ER，Stewart E. Uterine Fibroids：Burden and Unmet Medical Need [J]. Semin Reprod Med，2017， 35（6）：473-480.
[3] 朱丽娟，李冬华，张武芳，等.理冲汤对异种移植子宫肌瘤小鼠免疫因子MCP-1、ICAM-1表达的影响[J].世界中西医结合杂志，2017，12（1）：53-56.
[4] 张武芳，郑九波，李冬华，等.理冲汤调控人子宫肌瘤细胞MMP-2、TIMP-2表达的研究[J].世界中西医结合杂志，2015，10（8）：1073-1076.
[5] Raj D，Liu T，Samadashwily G，et al. Survivin repression by p53，Rb，and E2F2 in normal human melanocytes [J]. Carcinogenesis，2008，29（1）：194-201.
[6] 梅庆男，张卫平，冉冉，等.黄芪多糖对肺癌外周循环MDSC的影响及临床效果研究[J].中国现代医生，2017， 55（34）：10-13.
[7] 吴娇，王聪.黄芪的化学成分及药理作用研究进展[J].新乡医学院学报，2018，35（9）：755-760.
[8] 邓春，赵红艳，高美丽.黄芪活性成分抗肿瘤研究进展[J].国外医学：医学地理分册，2018，39（3）：276-280.
[9] 崔伟，刘爱珍，谢琼，等.黄芪多糖联合新辅助化疗TP方案对宫颈癌患者免疫抑制细胞Treg和MDSC的影响[J].华南国防医学杂志，2018，32（4）：238-241.
[10] 寇露露，刘海霞，邵妤，等.三棱、莪术抗肿瘤生物活性研究[J].吉林中医药，2017，37（7）：722-724.
[11] 冯娅茹，张文婷，李二文，等.三棱化学成分及药理作用研究进展[J].中草药，2017，48（22）：4804-4818.
[12] 倪雯婷，潘燕红，王爱云，等.破血消癥中药抗肿瘤转移研究进展[J].中草药，2016，47（24）：4472-4477.
[13] 姚远，仝立国，冯玛莉，等.黄芪-莪术不同提取物抗肿瘤作用研究[J].中国现代医生，2017，55（7）：33-36，169.
[14] Efremova M，Rieder D，Klepsch V，et al. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution [J]. Nat Commun，2018，9（1）：32.
[15] Bose S，Panda AK，Mukherjee S，et al. Curcumin and tumor immune-editing：resurrecting the immune system [J]. Cell Div，2015，10：6.
[16] Liu Y，Cao X. Immunosuppressive cells in tumor immune escape and metastasis [J]. J Mol Med，2016，94（5）：509-522.
[17] Monjazeb AM，Kent MS，Grossenbacher SK，et al. Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Anti-tumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies [J]. Clin Cancer Res，2016，22（17）：4328-3430.
[18] Fallarino F，Grohmann U. Using an Ancient Tool for Igniting and Propagating Immune Tolerance：IDO as an Inducer and Amplifier of Regulatory T Cell Functions [J]. Curr Med Chem，2011，18（15）：2215-2221.
[19] Selvan SR，Dowling JP，Kelly WK，et al. Indoleamine 2,3-dioxygenase（IDO）：Biology and Target in Cancer Immunotherapies [J]. Curr Cancer Drug Targets，2016，16（9）：755-764.
[20] Schafer CC，Wang Y，Hough KP，et al. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment [J]. Oncotarget，2016，7（46）：75407-75424.
[21] Lu L，Barbi J，Pan F. The regulation of immune tolerance by FOXP3 [J]. Nat Rev Immunol，2017，17（11）：703-717.
[22] Gerriets VA，Kishton RJ，Johnson MO，et al. Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression [J]. Nat Immunol，2016，17（12）：1459-1466.
[23] 刘家玲，王仕敏，卓召振，等.肿瘤微环境中靶向调节性T细胞免疫治疗策略[J].中国医药导报，2018，15（10）：46-50.
[24] Zhuo C，Xu Y，Ying M，et al. FOXP3+ Tregs：heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer [J]. Immunol Res，2015，61（3）：338-347. |
|
|
|
